A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 257,000 shares of ALNY stock, worth $62.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
257,000
Previous 146,600 75.31%
Holding current value
$62.5 Million
Previous $28.1 Million 36.88%
% of portfolio
0.01%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$146.51 - $198.2 $3.91 Million - $5.29 Million
-26,665 Reduced 40.01%
39,984 $5.98 Million
Q4 2023

Feb 14, 2024

BUY
$151.41 - $196.57 $10.1 Million - $13.1 Million
66,649 New
66,649 $12.8 Million
Q2 2023

Aug 14, 2023

SELL
$185.01 - $212.05 $13.8 Million - $15.9 Million
-74,773 Reduced 71.67%
29,563 $5.62 Million
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $18.8 Million - $24.2 Million
102,896 Added 7145.56%
104,336 $20.9 Million
Q4 2022

Feb 14, 2023

SELL
$185.53 - $241.31 $15.1 Million - $19.6 Million
-81,132 Reduced 98.26%
1,440 $342,000
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $10.4 Million - $17.4 Million
74,878 Added 973.2%
82,572 $16.5 Million
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $672,666 - $945,653
5,586 Added 264.99%
7,694 $1.12 Million
Q1 2022

May 16, 2022

SELL
$127.18 - $173.91 $8.73 Million - $11.9 Million
-68,660 Reduced 97.02%
2,108 $344,000
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $7.96 Million - $10.4 Million
49,889 Added 238.94%
70,768 $12 Million
Q3 2021

Nov 15, 2021

SELL
$169.75 - $207.73 $3.07 Million - $3.75 Million
-18,070 Reduced 46.39%
20,879 $3.94 Million
Q2 2021

Aug 16, 2021

SELL
$128.63 - $176.89 $10.8 Million - $14.9 Million
-84,277 Reduced 68.39%
38,949 $6.6 Million
Q1 2021

May 17, 2021

BUY
$126.83 - $175.69 $5.36 Million - $7.43 Million
42,265 Added 52.2%
123,226 $17.4 Million
Q4 2020

Feb 16, 2021

BUY
$122.97 - $147.0 $6.69 Million - $8 Million
54,428 Added 205.13%
80,961 $10.5 Million
Q3 2020

Nov 16, 2020

SELL
$121.19 - $165.49 $5.72 Million - $7.81 Million
-47,167 Reduced 64.0%
26,533 $3.86 Million
Q2 2020

Aug 14, 2020

SELL
$104.21 - $156.44 $3.82 Million - $5.73 Million
-36,658 Reduced 33.22%
73,700 $10.9 Million
Q1 2020

May 15, 2020

BUY
$93.12 - $133.99 $2.75 Million - $3.96 Million
29,585 Added 36.63%
110,358 $12 Million
Q4 2019

Feb 14, 2020

BUY
$74.51 - $124.23 $27,345 - $45,592
367 Added 0.46%
80,773 $9.3 Million
Q3 2019

Nov 14, 2019

SELL
$70.9 - $87.82 $62.8 Million - $77.8 Million
-885,638 Reduced 91.68%
80,406 $6.47 Million
Q2 2019

Aug 14, 2019

BUY
$65.86 - $92.79 $62.8 Million - $88.5 Million
953,740 Added 7751.46%
966,044 $70.1 Million
Q1 2019

May 15, 2019

SELL
$72.76 - $93.45 $1.26 Million - $1.62 Million
-17,316 Reduced 58.46%
12,304 $0
Q4 2018

Feb 14, 2019

SELL
$62.67 - $88.33 $366,995 - $517,260
-5,856 Reduced 16.51%
29,620 $2.16 Million
Q3 2018

Nov 13, 2018

SELL
$87.52 - $122.67 $106,074 - $148,676
-1,212 Reduced 3.3%
35,476 $0
Q2 2018

Aug 10, 2018

SELL
$88.31 - $107.8 $1.84 Million - $2.24 Million
-20,819 Reduced 36.2%
36,688 $0
Q4 2017

Feb 09, 2018

BUY
$114.49 - $139.98 $1.41 Million - $1.72 Million
12,286 Added 27.17%
57,507 $7.31 Million
Q3 2017

Nov 09, 2017

BUY
$72.53 - $118.27 $3.28 Million - $5.35 Million
45,221
45,221 $5.31 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.